



MEDIPURE HOLDINGS CLOSES PRIVATE PLACEMENT AND GRANTS INCENTIVE SHARES

June 11, 2015 – Vancouver, BC – Medipure Holdings Inc. (“**Medipure**” or the “**Company**”) [CSE:MDH] is pleased to announce that it has closed a private placement of its equity offering previously announced on November 13, 2014, for 37,500 of the Company’s common shares at a price of \$0.80 per share for total gross proceeds of \$30,000 (the “**Offering**”).

Medipure intends to use the proceeds from this Offering to advance its goal of conducting pioneering research into the development of cannabinoid-based medicines as prescription pharmaceuticals. Proceeds will also be allocated towards the Company’s operations, including product research and development. There were no finder fees paid in connection with the Offering.

Medipure is also pleased to announce that it has granted 5,000 of the Company’s common shares at a deemed price of \$0.80 per common share to each member of its newly-appointed Scientific Advisory Board for an aggregate grant of 15,000 common shares. The Company has also granted an aggregate of 265,000 of the Company’s common shares at a deemed price of \$0.80 per common share to certain other consultants as a bonus for services rendered during the period beginning April 1, 2015, to the present.

About Medipure Holdings Inc.

Medipure is developing an extensive network of strategic partnerships with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. Medipure will attempt to bring novel prescription medicines to market, providing patients with serious conditions valuable solutions that make a real difference to quality of life. Medipure will also seek to maximize the value of our products through rapid cost- effective product development, addressing market needs, and establishing strategic partnerships. Although Medipure has applied to Health Canada for a license to produce and distribute medical marijuana under the *Marihuana for Medical Purposes Regulations*, it has not yet received such a license and there is no guarantee that such a license will be granted to Medipure by Health Canada.

For more information, please contact:

Nathan Sellyn
Investor Relations
nsellyn@medipurepharma.com

Boris Weiss
Chief Executive Officer
boris@medipurepharma.com

Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward-looking information, including future-oriented financial information and financial outlooks, within the meaning of securities laws. This information is based on certain assumptions regarding expected growth, results of operations, performance, and business prospects and opportunities. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the companies cannot provide any assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release and the companies disclaim any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release shall not constitute an offer to sell or the solicitation of any offer to buy the securities in any jurisdiction. The securities offered have not been and will not be registered under the *United States Securities Act* of 1933, as amended (the "*U.S. Securities Act*"), and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the *U.S. Securities Act*. This press release is not intended for distribution to U.S. newswire services, and should not be disseminated within the U.S.